Page 1, 2, 3
Aristo Vojdani, PhD
Aristo Vojdani is presently a professor of neuroimmunology at the Carrick Institute for Graduate Studies and is a past associate professor at the Charles Drew/UCLA School of Medicine and Science. He obtained his MSc and PhD in the field of microbiology and clinical immunology with postdoctoral studies in tumor immunology at UCLA. His ongoing research, spanning a 45-year career, focuses on the role of environmental triggers such as toxic chemicals, infections, and dietary proteins and peptides, in complex diseases. Professor Vojdani's research and focus on predictive antibodies has resulted in the development of numerous antibody arrays for the detection of many autoimmune disorders. Of particular note are the arrays for autoimmune diseases that originate from the gut and manifest as attacks on the body's own tissues or organs, including the brain. An owner of 15 US patents for laboratory assessments, Professor Vojdani has published more than 130 articles in scientific journals. He is the CEO and Technical Director of Immunosciences Lab., Inc. in Los Angeles, California, and is the Chief Scientific Advisor for Cyrex Labs LLC, in Phoenix, Arizona. He sits on the editorial board of five scientific journals. In 2006, he was given the prestigious Herbert J. Rinkel Award by the American Academy of Environmental Medicine (AAEM) for excellence in teaching the techniques of environmental medicine. In 2009, he received the Linus Pauling, PhD Award by the American College for Advancement in Medicine, and in 2012 he was given the F. R. Carrick Research Institute's extremely distinguished Lifetime Achievement Award.
Cyrex Laboratories
Cyrex™ is a clinical immunology laboratory specializing in autoimmunity. The lab offers multi-tissue antibody testing for the early detection and monitoring of today's complex autoimmune conditions. Cyrex develops innovative arrays through continuous collaboration with leading experts in medical research and clinical practice. For additional information, see www.CyrexLabs.com.
Cyrex
5040 N. 15th Avenue, Suite 107
Phoenix, Arizona 85015
602-759-1245; Fax 602-759-8331
Editorial
Nancy Faass, MSW, MPH, is a writer in San Francisco who has worked on more than 40 books; she also provides articles, white papers, and writing for the Web via www.HealthWritersGroup.com. Thanks to Jerry Stine, NC, for technical support on this article; see www.Lifespan-Institute.com.
References
1 National Institutes of Health, The Autoimmune Diseases Coordinating Committee. Progress in autoimmune diseases research. Report to Congress. Published March 2005.
2 Notkins AL. New predictors of disease. Sci Am. 2007 296(3):72-79.
3 Virtanen M, et al. Cow 's milk consumption, HLA-DQB1 genotype, and type 1 diabetes. A nested case-control study of siblings of children with diabetes. Diabetes. 2000 49:912-917.
4 Karjalainen J, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. NEJM. 1992 327(5):302-307.
5 Vojdani A, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004 7(3):151-161.
6 Vojdani A, et al. The immunology of gluten sensitivity beyond the intestinal tract. Eur J Inflmm. 2008 6(2):49-57.
7 Ludvigsson JF, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013 62:43-52.
8 Lanzini A, et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Thera. 2009 29(12):1299-1308. doi:10.1111/j.1365-2036.2009.03992.x
9 Vojdani A, Tarash I. Cross-reaction between gliadin and different food and tissue antigens. FNS. 201344:20-32.
10 Kristjansson G, et al. Mucosal reactivity to cow's milk protein in coeliac disease." Clin Exp Immunol. 2007 147(3):449-455. doi:10.1111/j.1365-2249.2007.03298.x
11 Comino I, et al. Immunological determination of gliadin 33-mer equivalent peptides in beers as a specific and practical analytical method to assess safety for celiac patients. J Sci Food Agric. 2013 93(4):933-943. doi: 10.1002/jsfa.5830
12 Comino I, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease." Gut. 2011 60(7):915-922. doi:10.1136/gut.2010.225268
13 Vojdani A, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus Group A. J Neuroimmunol. 2002 129:168-177.
14 Vojdani A. For the assessment of intestinal permeability, size matters. Alter Ther Health Med. 2013 19(1):12-24.
15 Vojdani A. Antibodies as predictors of autoimmune diseases and cancer. Expert Opinion on Medical Diagnostics. 2008 2(6):593-605.
16 Devraj B, et al. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR. J Immunol. 2006 164:5788-5796.
17 Betterle C, et al. Update on autoimmune polyendocrine syndromes (APS). Acta Bio Medica. 2003 74:9-33.
18 Tian J, et al. T cell cross-reactivity between coxsackie virus and glutamate decarboxylase is associated with a murine susceptibility allele. J Exp Med. 1994 180(5):1979-1984.
19 Cavallo MG, et al. Cell-mediated immune response to beta casein in recent-onset insulin-dependent diabetes: implications for disease pathogenesis. Lancet. 1996 348:926-928.
Page 1, 2, 3 |
